2020
Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data
Shuey M, Perkins B, Nian H, Yu C, Luther JM, Brown N. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. BMJ Open 2020, 10: e033100. PMID: 32461291, PMCID: PMC7259833, DOI: 10.1136/bmjopen-2019-033100.Peer-Reviewed Original ResearchConceptsBody mass indexHigher body mass indexElectronic medical recordsBaseline systolic BPTherapy-resistant hypertensionBlood pressure responseRetrospective cohort studyDiastolic BPSystolic BPBP responseBaseline BPCohort studyChronic kidney disease stage 3Real-world clinical settingElectronic medical record dataMean systolic BPDisease stage 3Glomerular filtration rateIschemic heart diseasePressure responseMedical record dataClinical trial dataHigh-density lipoproteinLow-density lipoproteinAcademic medical center
2016
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Annals Of Internal Medicine 2016, 164: 705-14. PMID: 27110660, PMCID: PMC5178978, DOI: 10.7326/m15-2568.Peer-Reviewed Original ResearchConceptsHospitalized heart failureMini-Sentinel programCohort studyHeart failureAntihyperglycemic agentsPropensity score-matched analysisDipeptidyl peptidase-4 inhibitorsNew-user cohort studyU.S. FoodPrior cardiovascular diseaseRetrospective cohort studyPeptidase-4 inhibitorsSubgroup of patientsPrincipal discharge diagnosisDPP-4 inhibitorsSecond-generation sulfonylureasType 2 diabetesLarge cohort studyDisease risk scoreSitagliptin usersStudy drugHazard ratioDischarge diagnosisNinth RevisionResidual confounding
1997
Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema
Brown N, Snowden M, Griffin M. Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema. JAMA 1997, 278: 232-233. DOI: 10.1001/jama.1997.03550030072037.Peer-Reviewed Original ResearchConceptsACE inhibitor useAngiotensin converting enzyme (ACE) inhibitorsACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid programRecurrent angiotensin-converting enzyme inhibitor--associated angioedema.
Brown N, Snowden M, Griffin M. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA 1997, 278: 232-3. PMID: 9218671, DOI: 10.1001/jama.278.3.232.Peer-Reviewed Original ResearchConceptsACE inhibitor useACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid program
1996
Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema
Brown N, Ray W, Snowden M, Griffin M. Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema. Clinical Pharmacology & Therapeutics 1996, 60: 8-13. PMID: 8689816, DOI: 10.1016/s0009-9236(96)90161-7.Peer-Reviewed Original ResearchConceptsACE inhibitor useEnzyme (ACE) inhibitor-associated angioedemaInhibitor useACE inhibitorsRelative riskWhite subjectsACE inhibitor-associated angioedemaACE inhibitor doseRate of angiotensinRetrospective cohort studyRisk of angioedemaTennessee Medicaid programAssociation of racePotential confounding factorsEffect of doseSpecific ACE inhibitorDiuretic useCohort studyConcurrent medicationsPatient characteristicsPrevious hospitalizationAngioedemaInhibitor doseConfounding factorsYears of useAngiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites
Burkhart G, Brown N, Griffin M, Ray W, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites. Pharmacoepidemiology And Drug Safety 1996, 5: 149-154. PMID: 15073831, DOI: 10.1002/(sici)1099-1557(199605)5:3<149::aid-pds222>3.0.co;2-i.Peer-Reviewed Original ResearchCalcium channel blockersIncidence of angioedemaWhite patientsHigh riskGreater incidenceGreater riskEnzyme (ACE) inhibitor-associated angioedemaRate of angioedemaRetrospective cohort studyRisk of angioedemaACEI exposureACEI useACEI usersAngioedema incidenceCCB usersCohort studyAngioedema casesFirst episodeACEIsChannel blockersAngioedemaMedicaid recipientsFull cohortEnzyme inhibitorsChronic exposure